[Skip to Navigation]
January 1978

Pancreatic Cancer Treated With Carmustine, Fluorouracil, and Spironolactone: A Randomized Study

Author Affiliations

From the Division of Clinical Oncology (Drs Stephens, Hoogstraten, and Haas), Department of Medicine, and the Department of Biometry (Dr Clark), University of Kansas Medical Center, Kansas City.

Arch Intern Med. 1978;138(1):115-117. doi:10.1001/archinte.1978.03630250077022

A prospective randomized trial between two drug regimens in 38 patients with advanced pancreatic carcinoma was performed. The two-drug regimen consisted of carmustine and fluorouracil. The survival rate and response to these two drugs was compared to a three-drug regimen consisting of these same two drugs plus spironolactone. Objective partial responses were rare in both groups, being 3/18 in the two-drug group and 2/20 in the three-drug group. Life table analysis in previously untreated patients from time of treatment shows longer survival for the three-drug group, but this difference was not statistically significant.

(Arch Intern Med 138:115-117, 1978)